Pricing Log in Create free account
Friday 6 November 2026 Export KRYS’s income statement to Excel — free account

Krystal Biotech, Inc.

KRYS Healthcare Biotechnology

Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024.

Revenue
+30.2%
EPS
−22.3%
Free cash flow
+137.8%

Quarter to September 2026, against a year earlier

300.31 0.06 +0.02%
Market cap
$8.9B
P/E
39.2×
Fwd P/E
45.7×
Dividend yield
—
F-score
7/9
Altman Z
39.03
Beneish M
−2.27
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Krystal Biotech, Inc. (KRYS) EV/Sales

Alert me on EV/Sales

As of 6 November 2026, Krystal Biotech, Inc. (KRYS) trades at a EV/Sales of 17.0×. Over the past ten years it has ranged from 0.0× (June 2024) to 33.4× (July 2024); the current reading is higher than 87% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 16.2× 21.32%
FY2024 13.4× —
FY2023 0.0× —

Quarterly newest first

Period EV/Sales Change
Sep 2026 19.0× (17.33%)
Jun 2026 23.0× 42.33%
Mar 2026 16.2× (0.33%)
Dec 2025 16.2× 38.11%
9 more quarters

Against its own ten years

Low 0.0× High 33.4×
Ten-year median 0.0×
Current reading's percentile 87

EV/Sales against peers

Company EV/Sales
PCVX Vaxcyte, Inc. compare n/m
MDGL Madrigal Pharmaceuticals, Inc. compare 7.7×
TGTX TG Therapeutics, Inc. compare 10.8×
ARWR Arrowhead Pharmaceuticals, Inc. compare 11.3×
TWST Twist Bioscience Corporation compare 16.9×
KRYS Krystal Biotech, Inc. 17.0×
PTGX Protagonist Therapeutics, Inc. compare 28.1×
IBRX ImmunityBio, Inc. compare 60.3×
SYRE Spyre Therapeutics, Inc. compare 7,722×
Biotechnology industry median 9.0×
Healthcare sector median 3.6×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on KRYS